Vaccine efficacy in children six months to two years was 43.7 percent, and vaccine efficacy was 37.5 percent in the two to under six years age group.
Moderna said this was consistent with what had been observed among adults and the company was evaluating a third dose to lift efficacy levels. The trial comprised 11,700 pediatric volunteers in the United States and Canada, including 4,200 aged two to six years and 2,500 aged six to two months. The company added that, after consulting with the FDA, it is also applying to be authorized among children six to 11 for two-doses of 50 micrograms, and updating its application for authorization in kids aged 12 through 17.Last month, the FDA postponed a meeting of a panel to consider the Pfizer-BioNTech Covid vaccine for children younger than five, saying it required additional data on third doses. The companies said they expected that data to be ready by April.
Who the hell gave them their babies to do trials on.
🤣🤣🤣🤣🤣
Ba nnyela
ENCA staff babies first
No!
No thanks.
Investing today will save you the stress of financial crisis tomorrow.. Live the kind of life you want today by investing and trading Bitcoin option. Trade with a professional trader and start making good profits today. Bettyparksfx for transparency and trust.